At the cellular level, Enzalutamide treatment in the PAH model led to increased apoptosis in pulmonary artery endothelial cells, whereas activation of the Notch3/Hes5 pathway reduced apoptosis. Here, HES5 is linked to pulmonary arterial hypertension.